PUBLIC COMPANY
save$EVMNEvommune, Inc.
$EVMN13.57-9.59%Palo Alto, CA, USupdated 5h ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
view all catalysts →Active trials
- phase2Phase 2b Study of EVO756 in Adults With Atopic Dermatitis
- phase2Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)
- phase2Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis
- phase2A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria
- phase2Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis
Insider activity
source: SEC Form 4routine RSU / option mechanics (6)
- Apr 16, 26grantPatel Jeegar Pravinkumar · Chief Scientific Officer69,315 sh
- Apr 16, 26grantDrew Janice Suzann · Chief of Dev. Operations73,892 sh
- Apr 16, 26grantBauer Eugene · Chief Medical Officer51,117 sh
- Apr 16, 26grantCarver Kyle · Chief Financial Officer98,946 sh
- Apr 16, 26grantMoss Gregory S. · Chief Business & Legal Officer115,279 sh
- Apr 16, 26grantPena Luis C. · President & CEO291,420 sh
🐶 Hiring Signal
News
- Evommune's lead drug fails in chronic hives, stock sinksEvommune's shares {$EVMN} fell more than 30% on Monday morning after the biotech reported its first major trial readout since going public last year. In chronic spontaneous urticaria, a skin condit…endpoints · 1mo ago
Data sources
last refreshed 3m ago
Found something off?
comments(0)
5-min edit window · permanent after that